Angela Pham, MD
Rheumatology · Carrollton, GANPI 1437344603
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,730 of the $13,570 with a category attached, or 71.7%. Johnson & Johnson accounts for 85.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $11,447 and has fallen 98.2% since, to $211 in 2025.
Across 105 payments — averaging $129.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$12K
- AbbVie$707
- Novartis$261
- Amgen$222
- GSK$173
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$122
- plus $518 from 14 others
What the payments were for
- Consulting fees$9,73072%
- Travel & lodging$1,42410%
- Food & beverage$2,25017%
- Education$1661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 22 | $11,565 |
| AbbVie | 22 | $707 |
| Novartis | 14 | $261 |
| Amgen | 9 | $222 |
| GSK | 9 | $173 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $122 |
| Sanofi-aventis U.S. LLC | 6 | $91 |
| Mallinckrodt Hospital Products Inc. | 1 | $84 |
| Bristol Myers Squibb | 3 | $55 |
| Boehringer Ingelheim | 2 | $44 |
| Mallinckrodt Enterprises LLC | 3 | $41 |
| Genentech USA, Inc. | 3 | $39 |
| Sanofi | 1 | $27 |
| Avanir Pharmaceuticals, Inc. | 2 | $26 |
| Medexus Pharma, Inc. | 2 | $24 |
| Sobi, Inc | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Pfizer | 1 | $17 |
| Nalpropion Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,570 in reported general payments places this provider in the 70th percentile of 177 rheumatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 174 | $1,552,528 |
| Enbrel SureclickEtanercept | 203 | $1,501,913 |
| RinvoqUpadacitinib | 179 | $1,222,196 |
| KevzaraSarilumab | 114 | $487,601 |
| Skyrizi PenRisankizumab-Rzaa | 17 | $361,633 |
| Orencia ClickjectAbatacept | 61 | $332,835 |
| Actemra ActpenTocilizumab | 83 | $276,639 |
| Enbrel MiniEtanercept | 34 | $252,178 |
| ActemraTocilizumab | 46 | $225,284 |
| OtezlaApremilast | 39 | $194,486 |
| Xeljanz XrTofacitinib Citrate | 32 | $181,244 |
| BenlystaBelimumab | 48 | $159,882 |
| Cosentyx Unoready PenSecukinumab | 22 | $158,705 |
| SimponiGolimumab | 22 | $142,407 |
| Taltz AutoinjectorIxekizumab | 21 | $141,895 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $707 | $1,309,680192 claims |
| SanofiKevzara | $27 | $487,601114 claims |
| AmgenOtezla, Enbrel, Prolia | $222 | $348,73077 claims |
| GSKBenlysta | $173 | $159,88248 claims |
| Johnson & JohnsonSimponi | $11,565 | $142,40722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 177 rheumatology providers in Georgia.
Other rheumatology in Carrollton
- James MossellTifton$1.6M
- Gary MyersonAtlanta$1M
- Theresa Lawrence FordLawrenceville$410K
- William WilsonAtlanta$344K
- Jefrey LiebermanDecatur$247K
- Mohammed AbubakerMarietta$218K
- James HuntThomasville$160K
- Omar KhanCumming$145K
- Paul SutejAtlanta$140K
- Sung LimAtlanta$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.